Cramer's 'Mad Money' Recap: Ignore the Headlines
The market is also clamoring for restaurant stocks, with everything from fresh IPOs like Chuy's Holdings (CHUY) and Bloomin' Brands (BLMN) to old standbys including Red Robin Gourmet Burgers (RRGB) solidly in the black for the year.
With so many things going in its favor, Cramer said it's easy to see why the market quickly snapped up Noodles and continues to drive the stock higher. He said that while he wouldn't buy the stock at current levels, he would be tempted on any weakness.
Be Cautious on Onyx
Shares of Onyx Pharmaceuticals more than doubled on the news the company is being acquired, but Cramer reminded investors that risk-reward matters and in the case of this red-hot biotech, the easy money has already been made.
That's why Cramer said he'd ring the register and sell shares of Onyx, despite talks of the company receiving an even higher bid. "There are better ways to play this sector," he said, including some long-standing recommendations like Seattle Genetics (SGEN), Immunogen (IMGN) and BioMarin (BMRN).But investors truly looking to cash in on the long-term promise of the biotech group need to stick with the big boys, said Cramer, mainly Celgene and Gilead Sciences (GILD). He said both Celgene and Gilead have what it takes for the long term and he'd be a buyer of any of these names on the next market pullback that puts them on sale.
Lightning RoundIn the Lightning Round, Cramer was bullish on Hershey Foods (HSY), Walgreen (WAG), CVS Caremark (CVS), Bed Bath & Beyond (BBBY), Dean Foods (DF), Five Below (FIVE), Six Flags (SIX), Cedar Fair (FUN), Kodiak Oil & Gas (KOG) and Celldex Therapeutics (CLDX). Cramer was bearish on Vale (VALE), Pengrowth Energy Trust (PGH), EMC (EMC) and Oracle (ORCL).
Mad TweetsIn the "Mad Tweets" segment, Cramer responded to questions sent via Twitter to @JimCramer. Starting with a round of biotech names, Cramer said Trius Therapautics (TSRX) was "too hot to handle," but he would bless Array Biopharma (ARRY), which is up 27% so far this year. He said that investors missed the move in Cytokenetics (CYTK) if they're not already in it. When asked about Sony (SNE), Cramer said the stock is not expensive but he's not betting that a breakup is eminent. He was still bullish on Costco (COST), but said that Broadcom (BRCM) needed to be sold.
No Huddle OffenseIn his "No Huddle Offense" segment, Cramer sounded off against the notion that acquiring another company is a bad thing. He said that companies need only look at ConAgra (CAG) and B&G Foods (BGS) for two recent examples of acquisitions done right and ones that are making shareholders money. Cramer said he was hard-pressed to think of a recent merger that wasn't a big win for investors. That's why company managements need to "wake up and acquire" if they want to reinvigorate their stall share prices and growth rates. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. -- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts